Onconova Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.

Onconova Therapeutics, Inc.'s free cash flow has decreased 610.30K% from $-2.98M last year to $-18.18G, signaling decreasing performance

Onconova Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Onconova Therapeutics, Inc. has insufficient data to evaluate this check.

Onconova Therapeutics, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Onconova Therapeutics, Inc. carries no debt; interest obligations are fully covered.

Onconova Therapeutics, Inc.'s profit margin has increased (-100.00%) in the last year from -736.83% to 0.00%, signaling increasing performance

Onconova Therapeutics, Inc.'s short-term liabilities of $11.15G exceed its short-term assets of $7.98G, signaling financial risk

Onconova Therapeutics, Inc.'s return on assets of -178.40% is lower than the 5.00% threshold, indicating inefficient asset utilization

Onconova Therapeutics, Inc.'s return on equity of 489.90%, is higher than 15.00%, indicating good performance

Onconova Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Onconova Therapeutics, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

Onconova Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Onconova Therapeutics, Inc. has negative free cash flow, indicating cash burn

Onconova Therapeutics, Inc.'s yearly earnings has increased -650.67% since last year from $-1.67M to $9.17M, signaling increasing performance

Onconova Therapeutics, Inc.'s yearly revenue has increased 1.23M% since last year from $226.00K to $2.79G, signaling increasing performance

ROIC 283.33% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Onconova Therapeutics, Inc.'s 3-year revenue CAGR of 2.21K% is positive, indicating growing revenue over the past 3 years

Onconova Therapeutics, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Onconova Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Onconova Therapeutics, Inc. has insufficient data to evaluate this check.

Onconova Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Onconova Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Onconova Therapeutics, Inc. has an EV/EBITDA ratio of -55.20x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Onconova Therapeutics, Inc. is overvalued relative to its fair value price of -559.87K based on Earnings Fair Value model

Onconova Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Onconova Therapeutics, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Onconova Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue